Supporting Universal Hepatitis B Birth-Dose Vaccination

As the leading organization representing hepatology clinicians and researchers, AASLD is committed to advancing evidence-based policies that protect liver health. Vaccination against hepatitis B at birth is one of the most effective tools we have to prevent lifelong infection and reduce liver disease.

The CDC’s universal hepatitis B birth-dose recommendation is a proven public health success. Since its adoption in 1991, infant hepatitis B infections in the U.S. have declined by 95%, and more than 90,000 deaths have been prevented, ranking this vaccine among the most impactful childhood immunizations. A recent study also found that hepatitis B vaccination has prevented over 6 million infections and nearly 1 million hospitalizations in less than 30 years. The impact is clear.

Congratulations to Our 2025 Distinguished Award Recipients

Each year, AASLD proudly honors the individuals whose vision, leadership, and dedication drive the future of hepatology. AASLD’s Distinguished Awards are the highest honors we can bestow on those who exemplify excellence in service, mentorship, scientific advancement, and advocacy. 

Our 2025 Distinguished Awards recipients have made lasting contributions that extend far beyond their own work by building stronger communities of practice, advancing lifesaving research, and improving the lives of those affected by liver disease. 

We invite you to learn more about this year’s awardees and celebrate their accomplishments with us. 

Your Voice Can Shape AASLD’s New Transplant Guideline

Now through Sept. 19, AASLD invites public feedback on the proposed recommendations for the AASLD Practice Guideline on Adult Liver Transplantation: Diagnosis and Post-Transplant Management of Non-Graft-Related Complications.